H.C. Wainwright Says Market Remains Unconvinced on Lexeo Therapeutics, Inc. (LXEO)'s PKP2 Program

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. Lexeo Therapeutics, Inc. is placed sixteenth on our list.

TheFly reported on January 13 that H.C. Wainwright analyst Mitchell Kapoor lowered the price target for LXEO to $10 from $13 and maintained a Buy rating. The firm believes that the market is still not persuaded by LXEO’s recent PKP2 findings; the drop implies a lesser possibility of acceptance for the PKP2 program.

A day earlier, on January 12, Lexeo Therapeutics, Inc. (NASDAQ:LXEO) released preliminary results from its HEROIC-PKP2 Phase I/II trial of LX2020, which is an AAV-based gene therapy for PKP2-associated arrhythmogenic cardiomyopathy. There was no clinically significant complement activation, and LX2020 was usually well tolerated across dosage cohorts. PKP2 protein increased in a dose-dependent manner during treatment, averaging 93% in the low-dose group and 162% in the high-dose group. Premature ventricular contractions and non-sustained ventricular tachycardia are examples of arrhythmia features that often improve or stabilize.

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) is a clinical‑stage genetic medicine company focused on developing innovative gene and RNA therapies to target the underlying causes of cardiovascular diseases. It advances candidates for conditions like Friedreich’s ataxia and arrhythmogenic cardiomyopathy to improve long‑term heart health outcomes.

While we acknowledge the potential of LXEO as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Multibagger Stocks to Buy Heading into 2026 and 7 Best Rising Tech Stocks to Buy Now.

Disclosure: None.